Life Science Platform Promotes True Scientific Collaboration

SyynX Solutions GmbHCollexis (OTCBB: CLXS), a leading developer of high-definition search and discovery software, and their German partner, SyynX Solutions, announced they will preview a new life sciences social networking site to representatives from global book publishing and multimedia companies at the Frankfurt Book Fair in Frankfurt, Germany. This online community represents the next generation in social networks. The comprehensive system of pre-populated expert profiles, coupled with the ability to analyze all associated professional connections within the network, allows scientists and researchers across multiple organizations to share data and collaborate in ways never before considered.

Over the next few weeks, a controlled group of research thought leaders are testing the site for a public launch slated for January, when the site's name and web address will be formally released to the public. However, Frankfurt Book Fair attendees can gain access to the site at the companies' joint booth, number 417 in Hall 4.2, at any time during the conference.

Designed to promote collaborative research and development in advancing medical science, the site is the first social networking application to incorporate pre-generated expert profiles of over 1.4 million biomedical experts from more than 150 countries. It currently houses approximately 12 million pre-established network connections, automatically generated from over six million scientific publications from 6,500 journals. Contrary to the first generation social networks like Facebook and LinkedIn, this life science open platform goes to the next level and reflects the real-life activity network of the experts worldwide.

"Social networking isn't just for teenagers. There are a growing number of academics who are finding that online communities are the perfect way to share, collaborate and discuss their work," said Bill Kirkland, Collexis CEO. "But until now, an efficient way to coordinate the abundance of available digital information did not exist. The technology behind our site now makes it possible for researchers to collaborate in a way not previously possible."

"When a researcher logs into the site, available at no-charge, they will immediately see a robust synopsis of their publications, interests and network," added Kirkland. "The depth of this information, encompassing almost every published researcher in the biomedical sciences field worldwide, is what makes the site incredibly powerful. It also serves as a definitive source to identify relationships to others within the community, either by topic or geography."

The social networking site is based on Collexis' proprietary Fingerprint technology, a valuable research tool already employed by organizations such as: Johns Hopkins, The Mayo Clinic, Harvard University and The National Institute of Health.

"Taking the Collexis technology, which has become the platform of choice for leading biomedical companies, and combining it with a free social network application was really the next logical step," said Christian Herzog, MD, CEO of SyynX Solutions. "Thanks to the genius of Martin Schmidt, our chief technology officer, in collaboration with the Collexis leadership, the research community will now be able to instantaneously identify relevant expertise in a specific research area and start collaborating directly. Plus, we see the next generations of this platform expanding beyond biomedical research and into larger, global R&D development efforts."

About Collexis Holdings, Inc.
Collexis Holdings, Inc., a leading developer of High Definition Search and Discovery software since 1999, is headquartered in Columbia, South Carolina (USA) with two subsidiaries; Collexis Inc. in Columbia, South Carolina, USA and Collexis, B.V. in Geldermalsen, The Netherlands. Collexis proprietary technology builds conceptual profiles of text, called Fingerprints, from documents, websites, e-mails and other digitized content and matches them with a comprehensive list of pre-defined "fingerprinted" concepts to make research results more relevant and efficient. This matching of concepts eliminates the ambiguity and lack of priority associated with word searches. The results are often described as "finding needles in many haystacks." Through this novel approach, Collexis can build unique applications to search, index and aggregate information as well as prioritize, trend and predict data based on sources in multiple industries without the limitations of language or dialect. Collexis shares of common stock are traded under the symbol CLXS on the OTC Bulletin Board (OTC BB). For more information, please visit www.collexis.com.

About SyynX Solutions GmbH
SyynX Solutions GmbH is a German software company which focuses on text mining based applications for the areas of life science and health care. Collexis and SyynX are already co-operating closely since almost ten years on the technical and commercial level. The SyynX applications based on the Collexis fingerprint technology are used by customers like universities, pharmaceutical and biotech companies around the world. The text mining applications like the SyynX Knowledge Dashboard helps the user to analyze large text corpora without applying standard search approaches and provides him automatically with expert profiles, trends and knowledge discovery routines. For more information please visit www.syynx.de.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

Ancient viral DNA in human genome guards against i…

Viral DNA in human genomes, embedded there from ancient infections, serve as antivirals that protect human cells against certain present-day viruses, according to new res...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...